MindWalk Holdings (HYFT) Amortization - Intangibles (2020 - 2025)
MindWalk Holdings (HYFT) posted quarterly Amortization - Intangibles of $374.7 for Q1 2026, down 99.9% year-over-year from $366302.0 in Q1 2025, and up 2.52% quarter-over-quarter from $365.49 in Q4 2025.
Analysis
MindWalk Holdings (HYFT) Amortization - Intangibles (2020 - 2025) Analysis & Trends
MindWalk Holdings (HYFT) has reported Amortization - Intangibles for 6 consecutive years, with $374.7 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization - Intangibles fell 99.9% year-over-year to $374.7; the TTM figure through Apr 2026 stood at $740.18 (down 100.0% YoY), while the FY2025 annual figure was $1.1 million, down 37.35% from the prior year.
- Amortization - Intangibles improved to $374.7 in Q1 2026 per HYFT's latest filing, from $365.49 in the prior quarter.
- Across five years, Amortization - Intangibles topped out at $634.6 million in Q3 2023 and bottomed at $365.49 in Q4 2025.
- Historically, Amortization - Intangibles has averaged $117.7 million across 5 years, with a median of $524462.5 in 2024.
- Annual changes were most pronounced in 2023 — Amortization - Intangibles surged 62587.26% — and 2024, when it plunged 99.93%.
- MindWalk Holdings' Amortization - Intangibles stood at $836466.8 in 2022, then soared by 62587.26% to $524.4 million in 2023, then slumped by 99.93% to $371270.4 in 2024, then tumbled by 99.9% to $365.49 in 2025, then rose by 2.52% to $374.7 in 2026.
- Business Quant data shows HYFT's Amortization - Intangibles at $374.7 in Q1 2026, $365.49 in Q4 2025, and $492.61 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | MindWalk Holdings | 61.22 Mn | 52.95 Mn | 1.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2025 | 492,612.81 |
| Jan 31, 2025 | 366,301.96 |
| Oct 31, 2024 | 371,270.37 |
| Jul 31, 2024 | 366.62 Mn |
| Apr 30, 2024 | 73,014.51 |
| Jan 31, 2024 | 524,462.53 |
| Oct 31, 2023 | 524.36 Mn |
| Jul 31, 2023 | 634.58 Mn |
| Apr 30, 2023 | 973,327.77 |
| Jan 31, 2023 | 765,860.44 |
| Oct 31, 2022 | 836,466.82 |
| Apr 30, 2021 | 707,840.63 |
| Jan 31, 2021 | 727,699.13 |
| Oct 31, 2020 | 736,465.90 |
| Apr 30, 2020 | 968,364.38 |
| Jan 31, 2020 | 595,134.15 |